Cannabis Investors Eye Fed Rate Cuts as Debt Markets Stabilize
By Sheeba M. | April 27, 2026 Cannabis Investors Eye Fed Rate Cuts as Debt Markets Stabilize TL;DR: With bond markets cooling and Fed rate cuts back on the table, cannabis operators face lower borrowing costs—a potential lifeline for MSOs eyeing expansion and debt refinancing in late 2026. After months of tracking treasury yields and […]
Cannabis ETF Rally Signals Institutional Appetite
By Sheeba M. | April 27, 2026 Cannabis ETF Rally Signals Institutional Appetite TL;DR: ETF inflows hit $2.1B YTD as institutions gain exposure. Cannabis index funds now viable for 401k allocations—game changer for sector visibility and capital flow. Cannabis ETFs are experiencing unprecedented institutional adoption, with year-to-date inflows reaching $2.1 billion. This marks the first […]
Major Cannabis M&A Wave Reshapes Market in Q2
By Sheeba M. | April 27, 2026 Major Cannabis M&A Wave Reshapes Market in Q2 TL;DR: Consolidation accelerates as institutional investors eye undervalued cannabis operators. Watch CURLF, TCNNF for acquisition targets. The cannabis sector is experiencing a pivotal M&A surge as larger operators consolidate market share and investors hunt for value. With federal reform momentum […]
The Multistate Operator M&A Wave: Consolidation Signals Growth
By Sheeba M. | April 27, 2026 The Multistate Operator M&A Wave: Consolidation Signals Growth TL;DR: Cannabis MSO consolidation is accelerating. In Q1 2026, 11 major acquisitions were announced totaling $3.2B. This is typically a leading indicator of sector confidence—and suggests profitability is near. When multistate operators (MSOs) start consolidating aggressively, it usually means one […]
Cannabis Credit Crisis: Banks Still Avoiding the Industry
By Sheeba M. | April 27, 2026 Cannabis Credit Crisis: Banks Still Avoiding the Industry TL;DR: Despite federal rescheduling, major banks remain hesitant to finance cannabis operators. This creates a $12B funding gap that alternative lenders are exploiting—and it’s reshaping cannabis valuations across the sector. The cannabis industry has been waiting for federal policy to […]
Cannabis MSO Earnings Wave: Margin Pressure and Strategic Pivots Dominate Q1 Results
By Sheeba M. | April 26, 2026 Cannabis MSO Earnings Wave: Margin Pressure and Strategic Pivots Dominate Q1 Results TL;DR: Multi-state operators report Q1 earnings showing 8-12% margin compression as wholesale pricing pressures intensify. Green Thumb Industries, Curaleaf, and Trulieve all signal cost optimization as priority. Expect consolidation acceleration. The Margin Squeeze Hits Harder Than […]
The Cannabis Cash Flow Story Nobody’s Talking About: Why EBITDA Is the New EPS
By Sheeba M. | April 26, 2026 The Cannabis Cash Flow Story Nobody’s Talking About: Why EBITDA Is the New EPS TL;DR: Section 280E is still killing net income for cannabis operators, but smart investors are watching EBITDA and free cash flow instead. A 20%+ EBITDA margin operator can return cash to shareholders and fund […]
Cresco Labs Earnings Beat Sparks Rally as Margin Expansion Accelerates
By Sheeba M. | April 26, 2026 Cresco Labs Earnings Beat Sparks Rally as Margin Expansion Accelerates TL;DR: Cresco Labs posted Q1 2026 revenue of $412M, beating analyst expectations while EBITDA margins hit 22%—a key indicator that MSO consolidation and vertical integration are finally paying operational dividends. Wall Street is watching to see if this […]
Hemp’s Regulatory Time Bomb: November 2026 Changes Set to Reshape the Market
By Sheeba M. | April 26, 2026 Hemp’s Regulatory Time Bomb: November 2026 Changes Set to Reshape the Market TL;DR: New hemp-derived THC thresholds take effect November 2026, effectively recriminalizing much of the infused hemp market. Operators with compliant SKU portfolios will gain market share; over-leveraged hemp companies face existential risk. While headlines focus on […]
Medical Cannabis Rescheduling: The DEA’s Historic Move and What Investors Should Know
By Sheeba M. | April 26, 2026 Medical Cannabis Rescheduling: The DEA’s Historic Move and What Investors Should Know TL;DR: The DEA officially moved medical cannabis from Schedule I to Schedule III, unlocking banking access and reducing regulatory friction for state-licensed operators. Markets are repricing risk—but profitability remains the real story. In a historic reversal, […]